AECOM
Change company Symbol lookup
Select an option...
ACM AECOM
CLSN Celsion Corp
BAC Bank of America Corp
GPHBF Graphene 3D Lab Inc(British Columbia)
ITRI Itron Inc
LTTTX MFS Lifetime 2025 Fund Class R3
HLI Houlihan Lokey Inc
KICK Master Glazier's Karate International Inc
VIRT Virtu Financial Inc
FB Facebook Inc
Go

Industrials : Construction & Engineering | Mid Cap Blend
Company profile

AECOM is a global infrastructure consulting company. The Company provides professional services throughout the project lifecycle, from planning, architecture, design and engineering to program and construction management. Its segments include Americas, International and AECOM Capital (ACAP). The Americas segment provides planning, consulting, architectural and engineering design and construction management services to commercial and government clients in the United States, Canada and Latin America in end markets, such as transportation, water, government, facilities, environmental and energy. The International segment provides planning, consulting, architectural and engineering design services to commercial and government clients in Europe, the Middle East, Africa and the Asia-Pacific regions in end markets, such as transportation, water, government, facilities, environmental and energy. The ACAP segment has investments primarily in real estate projects.

Closing Price
$53.73
Day's Change
-0.23 (-0.43%)
Bid
--
Ask
--
B/A Size
--
Day's High
53.92
Day's Low
52.78
Volume
(Light)
Volume:
579,026

10-day average volume:
1,124,920
579,026

BIIB Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen Inc. Investors of Class Action and Encourages Investors to Contact the Firm

11:00 am ET November 19, 2020 (Globe Newswire) Print

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Biogen securities pursuant between October 22, 2019 and November 6, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/biib.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding aducanumab's effectiveness; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the FDA's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/biib or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Biogen you have until January 12, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

https://ml.globenewswire.com/media/a0da9a10-1592-437a-9c10-d30eeb243cb7/small/bgg-logo-jpg.jpg

https://ml.globenewswire.com/media/a0da9a10-1592-437a-9c10-d30eeb243cb7/small/bgg-logo-jpg.jpg

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.